Galectin Therapeutics
GALT
58 hedge funds and large institutions have $5.88M invested in Galectin Therapeutics in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 4 closing their positions.
1,022% more call options, than puts
Call options by funds: $819K | Put options by funds: $73K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
14% more funds holding
Funds holding: 51 → 58 (+7)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
16% less capital invested
Capital invested by funds: $7.02M → $5.88M (-$1.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.49M |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$133K |
| 3 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
+$83.8K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$74.1K |
| 5 |
AIG
American International Group
New York
|
+$73.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$670K |
| 2 |
Neuberger Berman Group
New York
|
-$149K |
| 3 |
Millennium Management
New York
|
-$123K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$49.6K |
| 5 |
Goldman Sachs
New York
|
-$43.5K |
GALT Hedge Fund Activity: Q4 2015 in Review
58 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2015, worth a combined $5.88M — down 16% from $7.02M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GALT positions and 4 closed out — a net gain of 7 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.49M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $670K sold.
- 58 institutional investors held Galectin Therapeutics (GALT) as of Q4 2015, up from 51 in Q3 2015.
- Funds reported $5.88M of Galectin Therapeutics stock for Q4 2015, down 16% quarter-over-quarter.
- 11 funds opened new Galectin Therapeutics positions in Q4 2015 and 4 closed out, a net change of +7 holders.
- The largest Galectin Therapeutics buyer in Q4 2015 was Sabby Management, an estimated $2.49M added.
- The largest Galectin Therapeutics seller in Q4 2015 was Cormorant Asset Management, an estimated $670K sold.
Based on aggregated 13F filings for Q4 2015.